International Flavors & Fragrances Inc. Earnings Recaps
Q2 2026
Aug 7, 2026
The stock responded positively with a 4.5% gain, driven by solid volume growth, disciplined margin management, and strong free cash flow generation, which support confidence in reaching full-year targets despite an uncertain macro environment.
Key takeaways
- Continuing operations achieved 4% sales growth and 8% EBITDA growth in the first half of 2026, underpinned by volume increases and productivity gains.
- Free cash flow improved significantly by $284 million year-over-year, reaching $378 million, supported by strong net working capital management.
- The announced divestiture of the Food Ingredients business for approximately $4.3 billion at a 10x EV/EBITDA multiple marks a major portfolio simplification and refocus on higher-growth, higher-margin segments.
- Stranded costs of about $100 million related to the divested Food Ingredients business are currently weighing on margins but are expected to be largely eliminated within two years through a remediation plan.
- Management plans to deploy divestiture proceeds to reduce debt by over $1 billion and initiate a $2.5 billion share repurchase program, reflecting confidence in long-term value creation.
Q1 2026
May 7, 2026
IFF’s shares rose 10.6% following the first quarter, driven by better-than-expected volume growth across all segments, strong margin expansion, and improved cash flow despite ongoing global uncertainties.
Key takeaways
- Revenue grew 3% to over $2.7 billion, supported by mid-single-digit volume growth in Health & Biosciences and low single-digit increases across Taste, Food Ingredients, and Scent.
- Adjusted EBITDA rose 8% to $568 million, with EBITDA margin expanding 110 basis points to 20.7%, the highest since Q2 2022, fueled by productivity improvements and favorable pricing.
- Taste segment sales increased 2% with an 18% EBITDA gain, led by volume and pricing strength, particularly in Greater Asia.
- Food Ingredients posted 3% sales growth and a 12% EBITDA increase, driven by strong volume (5%) and productivity; volume growth was the highest in several years.
- Health & Biosciences delivered 5% volume-driven sales growth across most businesses and 7% EBITDA growth, reflecting robust demand in Animal Nutrition and Food Biosciences.
Q3 2025
Nov 6, 2025
IFF delivered steady third quarter results, maintaining sales at approximately $2.7 billion despite a challenging macro environment. The company achieved a 7% increase in adjusted operating EBITDA, reflecting solid profitability and strategic investments for future growth.
Key takeaways
- Sales held flat year-over-year, with Scent and Taste businesses showing mid- and low single-digit growth, respectively.
- Adjusted operating EBITDA rose 7%, with an improved margin of 130 basis points, underscoring effective cost management.
- Significant progress on strategic initiatives, including new innovation centers and collaborations with BASF and Kemira, poised to enhance market offerings.
- The company reduced net debt to EBITDA ratio to approximately 2.5x and authorized a $500 million share repurchase, indicating a disciplined capital allocation approach.
- Year-to-date sales growth of 2% and ongoing portfolio optimization efforts, including completed divestitures, support IFF's long-term financial goals.